Blood-Based Biomarkers for Alzheimer Disease

This Viewpoint discusses areas of potential harm and actions needed to mitigate risk so that the use of blood-based biomarkers for Alzheimer disease can achieve the intended goal of improving care for all.

Corresponding Author: Heather E. Whitson, MD, MHS, Duke Aging Center, Duke University School of Medicine, DUMC Box 3003, Durham, NC 27710 (heather.whitson@duke.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.